FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) - Peer2Peer

FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

Jan 21, 2025

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.(Image credit: tadamichi/Getty Images/iStockphoto)

https://www.npr.org/sections/shots-health-news/2025/01/21/nx-s1-5269780/fda-allows-standalone-use-of-nasal-spray-antidepressant-spravato-esketamine

Respond, make new discussions, see other discussions and customize your news...
Log in.

To add this website to your home screen:

1. Tap

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Terms of Service